Nyxoah S.A. (NASDAQ:NYXH) Sees Large Increase in Short Interest

Nyxoah S.A. (NASDAQ:NYXH) was the target of a significant increase in short interest in February. As of February 28th, there was short interest totalling 100,200 shares, an increase of 27.2% from the February 13th total of 78,800 shares. Based on an average daily trading volume, of 43,000 shares, the days-to-cover ratio is presently 2.3 days. Currently, 0.7% of the shares of the company are sold short.

Institutional Investors Weigh In On Nyxoah

Institutional investors have recently added to or reduced their stakes in the stock. Kovack Advisors Inc. boosted its holdings in Nyxoah by 100.0% during the fourth quarter. Kovack Advisors Inc. now owns 20,000 shares of the company’s stock valued at $160,000 after purchasing an additional 10,000 shares in the last quarter. Ameriprise Financial Inc. acquired a new stake in Nyxoah during the fourth quarter valued at approximately $135,000. Vestal Point Capital LP acquired a new stake in Nyxoah during the fourth quarter valued at approximately $23,394,000. Renaissance Technologies LLC acquired a new stake in Nyxoah during the fourth quarter valued at approximately $187,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Nyxoah by 19.4% in the 4th quarter. Geode Capital Management LLC now owns 17,100 shares of the company’s stock worth $137,000 after acquiring an additional 2,774 shares in the last quarter.

Nyxoah Stock Up 1.8 %

NYXH stock opened at $10.60 on Wednesday. The company has a quick ratio of 4.95, a current ratio of 5.28 and a debt-to-equity ratio of 0.21. The business’s 50-day simple moving average is $10.32 and its 200 day simple moving average is $9.22. The company has a market cap of $361.04 million, a PE ratio of -5.67 and a beta of 1.42. Nyxoah has a twelve month low of $6.76 and a twelve month high of $18.95.

Nyxoah (NASDAQ:NYXH) last released its quarterly earnings data on Thursday, March 13th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.03). The company had revenue of $1.35 million for the quarter, compared to analyst estimates of $2.02 million. Nyxoah had a negative net margin of 1,043.93% and a negative return on equity of 51.68%. On average, research analysts anticipate that Nyxoah will post -1.91 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on NYXH. Stifel Nicolaus decreased their target price on Nyxoah from $16.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, March 14th. HC Wainwright reissued a “buy” rating and set a $17.00 target price on shares of Nyxoah in a research report on Friday, December 13th.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.